Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451403 | 0.84 | L3MBTL1 (0.43) | SMN1; SMN2NPC1RAB9AL3MBTL1HSD17B10 | |
| SCHEMBL6448386 | 0.82 | F2 (0.43) | SMN1; SMN2NPC1RAB9AL3MBTL1HSD17B10 | |
| SCHEMBL6452609 | 0.81 | ADORA2A (0.58) | SMN1; SMN2NPC1RAB9AL3MBTL1HSD17B10 | |
| SCHEMBL6458879 | 0.76 | KDM4E (0.44) | SMN1; SMN2NPC1RAB9AL3MBTL1HSD17B10 | |
| SCHEMBL11312873 | 0.74 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9AL3MBTL1HSD17B10 | |
| SCHEMBL6448821 | 0.74 | PLG (0.44) | SMN1; SMN2NPC1RAB9AL3MBTL1HSD17B10 | |
| SCHEMBL11320053 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AL3MBTL1HSD17B10 | |
| SCHEMBL6448741 | 0.73 | GRK6 (0.43) | SMN1; SMN2NPC1RAB9AL3MBTL1HSD17B10 | |
| SCHEMBL6448806 | 0.73 | MAPT (0.48) | SMN1; SMN2RAB9ATDP1KDM4EMEN1 | |
| SCHEMBL6450064 | 0.72 | GRK6 (0.47) | SMN1; SMN2NPC1RAB9AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | SMN1; SMN2 4633/4885NPC1 59/4885RAB9A 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.